Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutationThe approval of voretigene neparvovec-rzyl by the US Food and Drug Administration (FDA), in December 2017, marked the beginning of a new era in medicine in which many inherited diseases will be essentially corrected by gene therapy.Voretigene neparvovec-rzyl, with the trade name of Luxturna, is the first gene therapy for an inherited disease.It is intended for the treatment of RPE65 mutation-associated retinal dystrophy, making it the second commercially available treatment for inherited retinal disease (IRD) after retinal prostheses (Argus II and Alpha IMS) which were commercialized a few years earlier.Unlike retinal prostheses, voretigene neparvovec-rzyl modifies the course of the disease.Voretigene neparvovec-rzyl is composed of human RPE65 cDNA along with a cytomegalovirus enhancer and a hybrid chicken b-actin promoter incorporated into a recombinant adeno-associated virus 2 (AAV2).Following injection into the subretinal space, AAV2 enters retinal pigment epithelial (RPE) cells.While the viral vector remains in episomal form in the nucleus, without integrating into the host DNA, the enhancer and promoter facilitate expression of RPE65.Retinitis pigmentosa (RP) is the most common IRD, and Leber's congenital amaurosis (LCA) is a severe form of IRD presenting at birth or childhood.Affected patients present with nyctalopia and peripheral visual field defect followed by central vision loss in advanced stages of the disease.Currently, mutations in approximately 300 genes are known to cause IRD.Mutations in RPE65 account for approximately 2% of autosomal recessive RP and 16% of LCA. 1 Although an uncommon cause of IRD, several factors have made RPE65 a favorite target for gene therapy: 1) It causes autosomal recessive IRD, in which gene replacement is sufficient to treat the disease.2) About two decades ago, when gene delivery methods were being developed, RPE65 was one of only over a dozen genes that were known to cause IRD. 3) The relatively small size of RPE65 gene makes it possible to be carried by AAV2.4) The clinical course of LCA in which photoreceptor Peer review under responsibility of the Iranian Society of Ophthalmology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“In 2001, briard dogs with RPE65 mutation were successfully treated by gene therapy delivered through subretinal injection; the same study indicated that intravitreal delivery was not effective.(4) The positive results of a phase 1 human clinical trial in 2009 followed by a successful phase 3 trial in 2017 lead to the…”
BackgroundMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663 · cited 1×
“RPE65 mutations were first implicated in childhood IRD in 1997 by two independent groups of investigators.(2,3) In 2001, briard dogs with RPE65 mutation were successfully treated by gene therapy delivered through subretinal injection; the same study indicated that intravitreal delivery was not effective.”
BackgroundMutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606 · cited 1×
“RPE65 mutations were first implicated in childhood IRD in 1997 by two independent groups of investigators.(2,3) In 2001, briard dogs with RPE65 mutation were successfully treated by gene therapy delivered through subretinal injection; the same study indicated that intravitreal delivery was not effective.”
BackgroundMorimura, H., Fishman, G. A., Grover, S. A., Fulton, A. B., Berson, E. L., & Dryja, T. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3088 · Cited by 481 · cited 2×
“Mutations in RPE65 account for approximately 2% of autosomal recessive RP and 16% of LCA.(1) Although an uncommon cause of IRD, several factors have made RPE65 a favorite target for gene therapy: 1) It causes autosomal recessive IRD, in which gene replacement is sufficient to treat the disease.”
BackgroundHeier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30979-0 · Cited by 229 · cited 1×
“7) Although AAV2 is not pathogenic and has a favorable immunologic profile when delivered subretinally, a human clinical trial on age-related macular degeneration has suggested that pre-existent neutralizing anti-AAV2 serum antibodies may be associated with decreased efficacy of gene therapy when AAV2 is delivered int…”
Background
Cited by
Goertsen, D., Flytzanis, N. C., Goeden, N., Chuapoco, M. R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00969-4 · Cited by 420
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
The effects of PEGylation on LNP based mRNA delivery to the eye
Ryals, R. C., Patel, S., Acosta, C., McKinney, M., Pennesi, M. E., & Sahay, G. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241006 · Cited by 194
Gene therapy for inherited retinal diseases: Progress and possibilities
Hu, M. L., Edwards, T. L., O’Hare, F., Hickey, D. G., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1880863 · Cited by 118
Zhao, H., Lee, K.-J., Daris, M., Lin, Y., Wolfe, T., Sheng, J., Plewa, C., Wang, S., & Meisen, W. H. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.004 · Cited by 98
Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80
Gene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Vasconcelos, H. M., Lujan, B. J., Pennesi, M. E., Yang, P., & Lauer, A. K. (2020) · International Journal of Retina and Vitreous · doi:10.1186/s40942-020-00216-1 · Cited by 39
Touchard, E., Benard, R., Bigot, K., Laffitte, J.-D., Buggage, R., Bordet, T., & Behar-Cohen, F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.013 · Cited by 32
Redesigning therapies for pantothenate kinase–associated neurodegeneration
Munshi, M. I., Yao, S. J., & Ben Mamoun, C. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101577 · Cited by 32
“This strategy could allow for delivery of a normal PANK2 gene to targeted cells, thereby complementing the mutant allele in PKAN patients, an approach that has seen success in treatment of other rare diseases (39, 40).”
BackgroundResultGene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“5 The DNA could be delivered using viral or nonviral vectors; in this study, we review the differences.”
Self-citationViral-vector-delivered anti-angiogenic therapies to the eye
Koponen, S., Kokki, E., Kinnunen, K., & Ylä-Herttuala, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020219 · Cited by 24
“, Philadephia, PA, USA) for the treatment of inherited biallelic RPE65 mutation-associated retinal dystrophy [8].”
BackgroundInfluentialSiles, L., & Pomares, E. (2025) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2025.102482 · Cited by 4
Metadata
- Authors
- Ameri, H.
- Venue
- Journal of Current Ophthalmology
- Publisher
- Medknow
- Published
- 2018-03
- Volume
- 30
- Issue
- 1
- Pages
- 1-2
- ISSN
- 2452-2325 (ISSN-L)
- OpenAlex
- W2793446133
- Cited by
- 70
- References
- 7
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.